The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5551
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis ; day:8 ; month:4 ; year:2019 ; pages:1-5
Leukemia ; (8.4.2019), 1-5
- Creator
-
Mian, Afsar A.
Baumann, Ines
Liebermann, Marcus
Grebien, Florian
Superti-Furga, Giulio
Ruthardt, Martin
Ottmann, Oliver G.
Hantschel, Oliver
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-019-0468-y
- URN
-
urn:nbn:de:101:1-2019042723083533100308
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mian, Afsar A.
- Baumann, Ines
- Liebermann, Marcus
- Grebien, Florian
- Superti-Furga, Giulio
- Ruthardt, Martin
- Ottmann, Oliver G.
- Hantschel, Oliver
- SpringerLink (Online service)
Other Objects (12)
Role of SOCS proteins in FLT3-ITD and BCR-ABL mediated leukemogenesis
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
Expressionshemmung des humanen Onkogens Bcr-Abl durch RNA-Interferenz
Design and Synthesis of New Heterocyclic Bcr-Abl Inhibitors
Role of SOCS proteins in FLT3-ITD and BCR-ABL mediated leukemogenesis
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
Expressionshemmung des humanen Onkogens Bcr-Abl durch RNA-Interferenz
Design and Synthesis of New Heterocyclic Bcr-Abl Inhibitors
Role of SOCS proteins in FLT3-ITD and BCR-ABL mediated leukemogenesis
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
Expressionshemmung des humanen Onkogens Bcr-Abl durch RNA-Interferenz